Milestone Pharma's Net Loss Widens Amid Increased Commercial Spend

TL;DR

**Milestone's cash burn is accelerating, but fresh capital injections offer a lifeline for its high-stakes etripamil gamble.**

AI Summary

Milestone Pharmaceuticals Inc. reported a net loss of $11.922 million for the three months ended September 30, 2025, an increase from a net loss of $9.439 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened significantly to $45.649 million, compared to $29.156 million in the prior year. Revenue remained at $0 for both periods. Operating expenses saw a notable increase, with commercial expenses rising to $4.626 million for the three months and $20.107 million for the nine months in 2025, up from $1.911 million and $6.596 million respectively in 2024. Research and development expenses were stable at $3.940 million for the quarter but increased to $12.587 million for the nine months. The company's cash and cash equivalents increased to $46.685 million as of September 30, 2025, from $25.314 million at December 31, 2024, largely due to $49.094 million in cash provided by financing activities, including the issuance of common shares and warrants. Total shareholders' equity increased to $20.501 million from $13.147 million at year-end 2024, driven by significant equity raises.

Why It Matters

Milestone Pharmaceuticals' widening net loss and increased commercial expenses signal a critical phase for investors, as the company continues to invest heavily in its lead product candidate, etripamil, without generating revenue. The substantial capital raises, including $23.143 million from common shares and $22.920 million from Series A and B warrants, are crucial for funding ongoing clinical trials and potential commercialization efforts, but also dilute existing shareholders. For employees and customers, the focus on etripamil's development for cardiovascular indications like paroxysmal supraventricular tachycardia and atrial fibrillation holds promise for future treatments. In a competitive biopharmaceutical landscape, the success of etripamil is paramount for Milestone's long-term viability and market position.

Risk Assessment

Risk Level: high — The company reported a net loss of $45.649 million for the nine months ended September 30, 2025, a significant increase from $29.156 million in the prior year, indicating a substantial cash burn without any revenue generation. Furthermore, the company explicitly states it is subject to 'challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidate; delays or problems in the supply of its study drug or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and complying with applicable regulatory requirements.'

Analyst Insight

Investors should closely monitor the progress of etripamil's clinical trials and regulatory approvals, as the company's financial health is entirely dependent on its success. Given the significant capital raises and increased operating expenses, potential investors should assess the company's runway and future financing needs, while existing shareholders should be aware of potential further dilution.

Financial Highlights

debt To Equity

3.28

revenue

$0

operating Margin

N/A

total Assets

$87.750M

total Debt

$56.206M

net Income

-$45.649M

eps

-$0.60

gross Margin

N/A

cash Position

$46.685M

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $45.649M — Net Loss (for the nine months ended September 30, 2025, a significant increase from $29.156 million in 2024)
• $0 — Revenue (for both the three and nine months ended September 30, 2025 and 2024)
• $20.107M — Commercial Expenses (for the nine months ended September 30, 2025, up from $6.596 million in 2024)
• $12.587M — Research and Development Expenses (for the nine months ended September 30, 2025, up from $10.417 million in 2024)
• $46.685M — Cash and Cash Equivalents (as of September 30, 2025, an increase from $25.314 million at December 31, 2024)
• $49.094M — Cash Provided by Financing Activities (for the nine months ended September 30, 2025, up from $32.095 million in 2024)
• 85,169,344 — Common Shares Outstanding (as of September 30, 2025, up from 53,353,984 at December 31, 2024)
• $23.143M — Proceeds from Issuance of Common Shares (for the nine months ended September 30, 2025)
• $22.920M — Proceeds from Issuance of Series A and B Warrants (for the nine months ended September 30, 2025)
• $20.501M — Total Shareholders' Equity (as of September 30, 2025, up from $13.147 million at December 31, 2024)

Key Players & Entities

• Milestone Pharmaceuticals Inc. (company) — biopharmaceutical company focused on cardiovascular medicines
• etripamil (product) — lead product candidate, a rapid-onset nasal spray for cardiovascular indications
• Corxel Pharmaceuticals (company) — license agreement partner for etripamil in China, Hong Kong, Macau and Taiwan
• The Nasdaq Stock Market LLC (regulator) — exchange where MIST common shares are traded
• SEC (regulator) — Securities and Exchange Commission
• Montréal (location) — headquarters of Milestone Pharmaceuticals Inc.
• US GAAP (standard) — accounting principles generally accepted in the United States of America
• FASB (regulator) — Financial Accounting Standards Board
• ASU 2023-09 (standard) — Income Taxes (Topic 740): Improvements to Income Tax Disclosures
• Bloomberg (company) — financial news and data provider

FAQ

Risk Factors

• Increasing Net Loss and Burn Rate [high — financial]: The company reported a net loss of $11.922 million for Q3 2025, an increase from $9.439 million in Q3 2024. For the nine months, the net loss widened to $45.649 million from $29.156 million. This increasing loss, coupled with zero revenue, indicates a significant cash burn rate that will require continued financing.
• Significant Increase in Commercial Expenses [medium — operational]: Commercial expenses more than doubled for the three months ended September 30, 2025, rising to $4.626 million from $1.911 million in 2024. For the nine months, these expenses increased to $20.107 million from $6.596 million. This suggests increased investment in market preparation or pre-commercial activities.
• Continued Investment in R&D [medium — operational]: Research and development expenses remained relatively stable at $3.940 million for the quarter but increased to $12.587 million for the nine months ended September 30, 2025, up from $10.417 million in the prior year. This ongoing investment is critical for pipeline development but contributes to the overall net loss.
• Dependence on Financing Activities [high — financial]: The company's cash position increased to $46.685 million as of September 30, 2025, primarily due to $49.094 million in cash provided by financing activities. This highlights a heavy reliance on equity raises (common shares and warrants) to fund operations, as revenue remains at $0.
• Clinical Trial Success and Regulatory Approval [high — regulatory]: The company's future success is contingent on the successful completion of clinical trials for etripamil and subsequent regulatory approvals. Delays or failures in these trials, such as for paroxysmal supraventricular tachycardia or atrial fibrillation, pose significant risks.
• Market Adoption and Competition [medium — market]: Even with successful development and approval, market adoption of etripamil will depend on its efficacy, safety profile, pricing, and reimbursement compared to existing treatments. The competitive landscape for cardiovascular treatments is dynamic.

Industry Context

Milestone Pharmaceuticals operates in the biopharmaceutical sector, focusing on developing novel therapies. The industry is characterized by high R&D costs, long development cycles, significant regulatory hurdles, and intense competition. Success is heavily dependent on clinical trial outcomes and securing substantial funding to advance drug candidates through development and potential commercialization.

Regulatory Implications

The company faces significant regulatory risks related to the clinical development and potential approval of its lead drug candidate, etripamil. Delays or failures in Phase 3 trials for paroxysmal supraventricular tachycardia or other indications could impede progress. Successful navigation of the FDA approval process is critical for future revenue generation.

What Investors Should Do

1. Monitor R&D and Commercial Expense Burn Rate
2. Evaluate Progress of Clinical Trials
3. Assess Future Financing Needs
4. Analyze Debt Covenants and Conversion Terms

Key Dates

• 2025-09-30: Quarter End — Reported net loss of $11.922 million for the quarter and $45.649 million for the nine months. Cash and cash equivalents stood at $46.685 million, with total shareholders' equity at $20.501 million.
• 2024-12-31: Year End — Cash and cash equivalents were $25.314 million, and total shareholders' equity was $13.147 million, providing a baseline for the subsequent period's financial changes.

Glossary

Accumulated deficit

The total net losses of a company since its inception, minus any net profits. It represents the cumulative loss that has not been offset by profits. (Milestone Pharmaceuticals has an accumulated deficit of $413.194 million as of September 30, 2025, indicating that the company has historically incurred more expenses than revenues.)

Pre-funded warrants

A type of warrant that allows the holder to purchase a share of common stock at a nominal exercise price, effectively acting as a pre-paid share. They are often used in financing rounds to avoid immediate dilution. (Milestone Pharmaceuticals has 16,412,925 pre-funded warrants outstanding as of September 30, 2025, which represent a significant portion of its equity structure and potential future dilution.)

Commercial expenses

Costs incurred by a company related to marketing, sales, and distribution of its products or services. For a pre-revenue biotech, this often includes market research, pre-launch activities, and building a commercial infrastructure. (The substantial increase in commercial expenses to $20.107 million for the nine months ended September 30, 2025, suggests significant investment in preparing for potential future product launches.)

Senior secured convertible notes

Debt instruments that pay interest and can be converted into a predetermined amount of the issuer's equity. 'Senior secured' means they have a high priority in repayment and are backed by collateral. (Milestone Pharmaceuticals has $56.206 million in senior secured convertible notes outstanding, representing a significant portion of its liabilities and a potential source of future equity dilution upon conversion.)

Year-Over-Year Comparison

Compared to the prior year, Milestone Pharmaceuticals has seen a significant widening of its net loss, increasing from $29.156 million to $45.649 million for the nine months ended September 30, 2025. This is driven by a substantial increase in commercial expenses, which more than tripled for the nine-month period. While R&D expenses saw a moderate increase, revenue remains at $0. The company's cash position has improved due to substantial financing activities, but the overall financial picture remains bearish due to the escalating losses and lack of revenue.

Filing Documents

• mist-20250930x10q.htm (10-Q) — 1708KB
• mist-20250930xex31d1.htm (EX-31.1) — 12KB
• mist-20250930xex31d2.htm (EX-31.2) — 12KB
• mist-20250930xex32d1.htm (EX-32.1) — 9KB
• 0001104659-25-109689.txt ( ) — 7071KB
• mist-20250930.xsd (EX-101.SCH) — 44KB
• mist-20250930_cal.xml (EX-101.CAL) — 42KB
• mist-20250930_def.xml (EX-101.DEF) — 197KB
• mist-20250930_lab.xml (EX-101.LAB) — 367KB
• mist-20250930_pre.xml (EX-101.PRE) — 301KB
• mist-20250930x10q_htm.xml (XML) — 1361KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Loss 4 Condensed Consolidated Statements of Shareholders' Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 33 PART II. OTHER INFORMATION 33 Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3. Defaults Upon Senior Securities 39 Item 4. Mine Safety Disclosures 39 Item 5. Other Information 40 Item 6. Exhibits 41 Table of Contents "Milestone Pharmaceuticals" and the Milestone logo appearing in this Quarterly Report on Form 10-Q are unregistered trademarks of Milestone Pharmaceuticals Inc. All other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q may be referred to without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto. This Quarterly Report on Form 10-Q contains references to United States dollars and Canadian dollars. All dollar amounts referenced, unless otherwise indicated, are expressed in United States dollars. References to "$" are to United States dollars and references to "C$" are to Canadian dollars. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "positioned," "potential," "seek," "should," "target," "will," "would" and other similar expressi

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Milestone Pharmaceuticals Inc. Condensed Consolidated Balance Sheets (Unaudited) (in thousands of US dollars, except share data) September 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 46,685 $ 25,314 Short-term investments 35,900 44,381 Research and development tax credits receivable 808 901 Prepaid expenses 2,577 1,840 Other receivables 700 1,490 Total current assets 86,670 73,926 Operating lease right-of-use assets 944 1,376 Property and equipment 136 197 Total assets $ 87,750 $ 75,499 Liabilities, and Shareholders' Equity Current liabilities Accounts payable and accrued liabilities $ 10,041 $ 7,555 Operating lease liabilities 483 571 Total current liabilities 10,524 8,126 Operating lease liabilities, net of current portion 519 874 Senior secured convertible notes 56,206 53,352 Total liabilities 67,249 62,352 Shareholders' Equity Common shares, no par value, unlimited shares authorized, 85,169,344 shares issued and outstanding as of September 30, 2025, 53,353,984 shares issued and outstanding as of December 31, 2024 311,776 288,048 Pre-funded warrants - 16,412,925 issued and outstanding as of September 30, 2025 and 12,910,590 as of December 31, 2024 55,649 53,076 Additional paid-in capital 66,270 39,568 Accumulated deficit ( 413,194 ) ( 367,545 ) Total shareholders' equity 20,501 13,147 Total liabilities and shareholders' equity $ 87,750 $ 75,499 The accompanying notes are an integral part of these interim condensed consolidated financial statements. 3 Table of Contents Milestone Pharmaceuticals Inc. Condensed Consolidated Statements of Loss (Unaudited) (in thousands of US dollars, except share and per share data) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Revenue $ — $ — $ — $ — Operating ex

View Full Filing

View this 10-Q filing on SEC EDGAR